A Look At The Proposed EU IP Exception To Promote Generic, Biosimilar Industry Competitiveness 16/11/2018 by David Branigan, Intellectual Property Watch 1 Comment The European Commission has proposed an exception to the extended period of patent protection that the European Union provides to original drug manufacturers for certain products, in order to boost the competitiveness of EU generic and biosimilar industries in global markets. The exception will allow EU generic and biosimilar companies to manufacture protected drugs for export during this patent extension period. Stakeholders are so far unhappy with the exception. Meanwhile, studies analyse its potential economic impacts and legal implications, and the Commission remains confident that safeguards it is putting in place will keep the lower-priced medicines from making their way back into the EU.
Global Biotech Industry Revisits Geneva, Seeks To Build Relationships To Help Shape Policies 14/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment A global association representing biotechnology industries last week made a second annual visit to Geneva’s institutions to raise awareness of how the industry works, its needs, and how the association could participate better in policymaking. Dismissing fears of industry unduly influencing public policies, two representatives of the association sat down with Intellectual Property Watch’s Catherine Saez to explain the importance of biotechnology in solving the problems of the world, and the need to raise awareness of the perspective of the biotechnology sector.
Key Hepatitis C Drug Licensed To Medicines Patent Pool, Access Expanded For LMICs 12/11/2018 by David Branigan, Intellectual Property Watch 2 Comments A key drug to treat hepatitis C has been licensed to the Medicines Patent Pool, enabling generic production and expanding affordable access to the drug in low and middle-income countries, excluding the very largest. The agreement between the Pool and AbbVie had been over a year in the making, MPP Executive Director Charles Gore told Intellectual Property Watch.
WTO TRIPS Council Debates Competition Law, Plain Packaging’s Spread To Other Products 12/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Trade Organization intellectual property committee met last week with lively discussions on the benefit of IP rights protection for new businesses, and on the role of competition law to prevent abuses of those rights and in particular ensure greater access to medicines. Also, considering the recent WTO Dispute Settlement Body ruling on the tobacco plain packaging, some countries warned against this decision becoming a precedent and spreading to other goods, and undermining trademark protection.
Report Finds “Overpatenting”, Overpricing Of Top Diabetes Drug In US 05/11/2018 by David Branigan, Intellectual Property Watch 1 Comment Non-profit patent researchers studying the most prominent prescription insulin drug to treat diabetes in the United States found it is “overpatented” and “overpriced,” enabling unwarranted price-hikes resulting in rising costs for patients and taxpayers.
WTO TRIPS Council Agenda: IP Key For New Businesses, Competition Law To Counter Abuses 05/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment World Trade Organization intellectual property committee members gather this week for their annual autumn session. On the agenda are now-usual topics looking at intellectual property from two perspectives: IP as an indispensable tool for innovation in particular in the new economy, and IP as a potential threat to access if misused. In addition, India has put forward further questions on goods in transit to the European Union in its directive on custom enforcement of IP rights.
Lurking In USMCA – IP Provisions With An International Agenda 30/10/2018 by Steven Seidenberg for Intellectual Property Watch Leave a Comment Donald Trump is no fan of international norms or rules. He’s made this clear on numerous occasions, including during his two speeches at the United Nations. It is surprising, therefore, that one of the few international deals he has made as president – the recently announced treaty replacing NAFTA – contains IP provisions whose main purposes seem to be extending US rules overseas and establishing IP norms for future international agreements.
New Report: Mitigating Patent Linkage To Promote Medicines Access In LMICs 26/10/2018 by David Branigan, Intellectual Property Watch 1 Comment A new report reviews how patent linkage mechanisms have been implemented in South Korea, Australia, Canada, and the United States, and identifies precedents for how low and middle-income countries (LMICs) can retain and exploit “constructive ambiguities” in trade treaty text to mitigate the impacts of patent linkage mechanisms and promote the timely availability of generic medicines.
US Releases New Medicare Drug Plan To “Pay The Prices Other Countries Pay” 26/10/2018 by David Branigan, Intellectual Property Watch Leave a Comment The United States Department of Health and Human Services has released a new plan intended to reduce drug prices for some patients on Medicare, based on an international pricing index model. In his announcement of the plan, President Trump said the US would save money “for our seniors by paying the prices other countries pay. Nothing special, just the prices that other countries pay.”
Investing In New Antibiotic Research: Difficult Equation Discussed At World Investment Forum 25/10/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The diminishing arsenal of efficient antibiotics to fight bacteria is a threat denounced by many, but investment in research and development of new antibiotics is seen as lagging. As the danger of getting back to a pre-antibiotic age is increasing, alternative ways of financing new antibiotics are being discussed. At the World Investment Forum this week, a panel looked into innovative means of investment, and ways to attract private investors to this field.